The agreement will apply Evotec’s integrated drug discovery expertise and technologies to progress novel small molecules for the treatment of anaemia from discovery into lead optimisation.
Evotec will use scientists based at its European and Indian sites covering in vitro biology, medicinal chemistry, and in vitro and in vivo pharmacology. The programme will be funded through research funding and success-based milestones.
Evotec CEO Werner Lanthaler said that the company is committed to identifying a preclinical candidate within an agreed budget.
“This will allow us to fully integrate and leverage all of our research sites and scientists to efficiently deliver a preclinical candidate,” Lanthaler said.